Free Newsletter

FEATURES >> 15 Top Blockbuster Contenders | 10 Promising Therapeutic Vaccines

Related Topics >> Drug Trials | sales and marketing | Novartis | COPD

SPOTLIGHT: Novartis plans Phase III trial

November 28, 2006 — 7:01pm ET

ALSO NOTED: Novartis plots $700M biotech plant; Genzyme wins marketing approval; Glenmark, Forest to pursue Phase II; and much
PhRMA's COPD pipeline report spotlights blockbuster hopefuls
Novartis signals serious U.S. delay for blockbuster COPD program
Novartis wins FDA OK of low-dose COPD therapy
Novartis unveils more promising Ph3 data on COPD program

Tools

Subscribe
Email
Print
Contact Author
Reprint

Vectura is touting an announcement from Novartis that it will begin a late-stage trial of a new COPD therapy in 2007 that incorporates a drug Vectura developed. Novartis expects to ask for marketing approval of QVA149--a combinatorial therapy--in 2010. Report

SHARE
WITH: